Published in Br J Dermatol on May 01, 1990
Systemic retinoids in the management of ichthyoses and related skin types. Dermatol Ther (2013) 1.06
Dental Treatments under the General Anesthesia in a Child with Keratitis, Ichthyosis, and Deafness Syndrome. Case Rep Dent (2013) 0.95
Keratitis-Ichthyosis-Deafness syndrome: A rare congenital disorder. Indian Dermatol Online J (2012) 0.78
Connexin 26 (GJB2) mutation in an Argentinean patient with keratitis-ichthyosis-deafness (KID) syndrome: a case report. BMC Med Genet (2016) 0.77
Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res (2001) 4.87
Microarrays: biotechnology's discovery platform for functional genomics. Trends Biotechnol (1998) 4.25
Influenza virus NS1 protein counteracts PKR-mediated inhibition of replication. J Virol (2000) 3.77
Epidermal Langerhans cells--a target for HTLV-III/LAV infection. J Invest Dermatol (1987) 3.41
Epiluminescence microscopy. A useful tool for the diagnosis of pigmented skin lesions for formally trained dermatologists. Arch Dermatol (1995) 3.34
Epidermal Langerhans cells bear Fc and C3 receptors. Nature (1977) 3.21
Diagnostic accuracy of dermoscopy. Lancet Oncol (2002) 3.14
Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med (1987) 3.13
Frequency and characteristics of enlarging common melanocytic nevi. Arch Dermatol (2000) 2.75
Impact of landscape management on the genetic structure of red squirrel populations. Science (2001) 2.34
Ultraviolet light depletes surface markers of Langerhans cells. J Invest Dermatol (1981) 2.28
Expression of Thy-1 antigen by murine epidermal cells. J Invest Dermatol (1983) 2.20
Phototesting and dosimetry for photochemotherapy. Br J Dermatol (1977) 2.17
In vivo epiluminescence microscopy of pigmented skin lesions. I. Pattern analysis of pigmented skin lesions. J Am Acad Dermatol (1987) 1.90
Ecstasy pill testing: harm minimization gone too far? Addiction (2001) 1.85
Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol (1998) 1.82
The fine structure of the Langerhans cell granule. J Cell Biol (1967) 1.79
Evidence of HLA-DR antigen biosynthesis by human keratinocytes in disease. J Exp Med (1984) 1.75
Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet (2000) 1.68
The langerhans cell. Curr Probl Dermatol (1972) 1.67
Wells' syndrome is a distinctive disease entity and not a histologic diagnosis. J Am Acad Dermatol (1988) 1.62
Methadone maintenance and tuberculosis treatment. BMJ (1996) 1.61
Antigen presentation by murine epidermal langerhans cells and its alteration by ultraviolet B light. J Immunol (1981) 1.60
Cyclosporin A suppresses ICAM-1 expression by papillary endothelium in healing psoriatic plaques. J Invest Dermatol (1991) 1.60
Double-blind trial of botulinum A toxin for the treatment of focal hyperhidrosis of the palms. Br J Dermatol (1997) 1.60
Human epidermal T cells predominantly belong to the lineage expressing alpha/beta T cell receptor. J Exp Med (1990) 1.57
Ultrastructural localization of immunoglobulins in bullous pemphigoid skin. Employment of a new peroxidase-antiperoxidase multistep method. J Invest Dermatol (1975) 1.57
Uptake, intracellular transport and degradation of exogenous protein by Langerhans cells. An electron microscopic-cytochemical study using peroxidase as tracer substance. J Invest Dermatol (1970) 1.56
Exploring the genetic link between RLS and ADHD. J Psychiatr Res (2009) 1.55
Permeability of the epidermis and the phagocytic activity of keratinocytes. Ultrastructural studies with thorotrast as a marker. J Ultrastruct Res (1971) 1.55
[Odland bodies (Membrane coating granules, keratinosomes) as epidermal lysosomes. An electron microscopic-cytochemical contribution on the cornification process of the skin]. Arch Klin Exp Dermatol (1967) 1.51
bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med (1998) 1.50
Overweight and obesity in children with Attention-Deficit/Hyperactivity Disorder. Int J Obes Relat Metab Disord (2004) 1.48
Treatment of metastatic malignant melanoma with dacarbazine plus fotemustine. Eur J Cancer (1998) 1.48
Immunoelectron microscopic characterization of human dermal lymphatic microvascular endothelial cells. Differential expression of CD31, CD34, and type IV collagen with lymphatic endothelial cells vs blood capillary endothelial cells in normal human skin, lymphangioma, and hemangioma in situ. J Histochem Cytochem (1998) 1.47
Treatment of psoriatic arthritis by extracorporeal photochemotherapy. Br J Dermatol (1990) 1.47
Upper keratinocytes of psoriatic skin lesions express high levels of NAP-1/IL-8 mRNA in situ. J Invest Dermatol (1991) 1.43
Skin tumors in the European PUVA Study. Eight-year follow-up of 1,643 patients treated with PUVA for psoriasis. J Am Acad Dermatol (1987) 1.42
Statistical evaluation of epiluminescence microscopy criteria for melanocytic pigmented skin lesions. J Am Acad Dermatol (1993) 1.41
Erythema multiforme associated human autoantibodies against desmoplakin I and II: biochemical characterization and passive transfer studies into newborn mice. J Invest Dermatol (1998) 1.41
Substance misuse among health care workers: national survey of occupational physicians. Occup Med (Lond) (2012) 1.40
Treatment of young patients with HNF1A mutations (HNF1A-MODY). Diabet Med (2014) 1.40
Multiple apocrine hidrocystomas on the eyelids. Am J Dermatopathol (1989) 1.39
[Photochemotherapy of psoriasis: clinical experiences with 152 patients (author's transl)]. Dtsch Med Wochenschr (1975) 1.38
Molecular analysis of plant migration and refugia in the Arctic. Science (2000) 1.37
Analysis of illicit ecstasy tablets: implications for clinical management in the accident and emergency department. J Accid Emerg Med (1999) 1.35
Quantitative studies on the Langerhans cell population of guinea pig epidermis. J Invest Dermatol (1967) 1.31
[The Langerhans cells. Results of newer experimental studies. I]. Arch Klin Exp Dermatol (1967) 1.30
Langerhans cells as stimulator cells in the murine primary epidermal cell-lymphocyte reaction: alteration by UV-B irradiation. J Invest Dermatol (1982) 1.30
A genome-wide scan for attention-deficit/hyperactivity disorder in 155 German sib-pairs. Mol Psychiatry (2006) 1.29
P45, an extracellular 45 kDa protein of Listeria monocytogenes with similarity to protein p60 and exhibiting peptidoglycan lytic activity. Arch Microbiol (2000) 1.27
Generalized atrophic benign epidermolysis bullosa. Arch Dermatol (1982) 1.27
Langerhans' cells are an actual site of HIV-1 replication. Intervirology (1988) 1.27
Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol (1995) 1.27
Endothelial cell tube formation depends on cadherin 5 and CD31 interactions with filamentous actin. J Immunol (1997) 1.25
An electron microscopic study on the extraneous coat of keratinocytes and the intercellular space of the epidermis. J Invest Dermatol (1968) 1.24
Ultrastructural localization of nucleoside triphosphatase in Langerhans cells. J Invest Dermatol (1967) 1.22
Mutation screen of the brain derived neurotrophic factor gene (BDNF): identification of several genetic variants and association studies in patients with obesity, eating disorders, and attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet (2005) 1.22
Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes. Br J Clin Pharmacol (1999) 1.21
Cannabis use in patients with multiple sclerosis. Mult Scler (2006) 1.21
Ultrastructural localization of pemphigus autoantibodies within e epidermis. Nature (1971) 1.21
Mechanism of UV-B-induced impairment of the antigen-presenting capacity of murine epidermal cells. J Immunol (1983) 1.20
Induction of UV light tolerance by PUVA in patients with polymorphous light eruption. Br J Dermatol (1978) 1.20
In vivo epiluminescence microscopy of pigmented skin lesions. II. Diagnosis of small pigmented skin lesions and early detection of malignant melanoma. J Am Acad Dermatol (1987) 1.19
Immunofluorescence mapping of antigenic determinants within the dermal-epidermal junction in the mechanobullous diseases. J Invest Dermatol (1981) 1.17
Follow-up of melanocytic skin lesions with digital epiluminescence microscopy: patterns of modifications observed in early melanoma, atypical nevi, and common nevi. J Am Acad Dermatol (2000) 1.17
[The permeability of the intercellular space of the epidermis for low molecular weight protein. Electron microscopic cytochemical studies with peroxidase as a tracer substance]. Arch Klin Exp Dermatol (1969) 1.17
Photoprotective effect of a psoralen-UVA-induced tan. Arch Dermatol Res (1978) 1.17
Interleukin 2 receptors on cultured murine epidermal Langerhans cells. J Immunol (1986) 1.16
Leu-3/T4 expression on epidermal Langerhans cells in normal and diseased skin. J Invest Dermatol (1986) 1.16
[Uptake, intracellular transport, and degradation of exogenous protein by keratinocytes. Electron microscopy and cytochemical study using peroxidase as a tracer substance]. Arch Klin Exp Dermatol (1969) 1.15
Epidermal lysosomes. Electron microscopic-cytochemical studies. Arch Dermatol (1970) 1.15
MCP-1 mRNA expression in basal keratinocytes of psoriatic lesions. J Invest Dermatol (1993) 1.15
Generalized eruptive histiocytoma. Enzyme histochemistry and electron microscopy. Arch Dermatol (1967) 1.14
The use of solid-phase radioimmunoassay techniques for serodiagnosis of human plague infection. Bull Pan Am Health Organ (1980) 1.13
In vivo epiluminescence microscopy: improvement of early diagnosis of melanoma. J Invest Dermatol (1993) 1.11
Novel Ras antagonist blocks human melanoma growth. Proc Natl Acad Sci U S A (1999) 1.10
The disappearance and regeneration of Langerhans cells following epidermal injury. J Invest Dermatol (1968) 1.10
Transmission disequilibrium of polymorphic variants in the tryptophan hydroxylase-2 gene in attention-deficit/hyperactivity disorder. Mol Psychiatry (2005) 1.09
Phagocytosis of latex beads by epidermal keratinocytes in vivo. J Ultrastruct Res (1972) 1.08
Maturational steps of bone marrow-derived dendritic murine epidermal cells. Phenotypic and functional studies on Langerhans cells and Thy-1+ dendritic epidermal cells in the perinatal period. J Immunol (1989) 1.07
The Langerhans cell. J Invest Dermatol (1983) 1.06
Long term behavioural outcome after neonatal arterial switch operation for transposition of the great arteries. Arch Dis Child (2002) 1.06
Experimental staphylococcal toxic epidermal necrolysis (TEN) in adult humans and mice. J Lab Clin Med (1974) 1.05
Dermal microvascular endothelial cells express CD32 receptors in vivo and in vitro. J Immunol (1996) 1.04
A genetically engineered influenza A virus with ras-dependent oncolytic properties. Cancer Res (2001) 1.04
Staphylococcal toxic epidermal necrolysis: pathogenesis and studies on the subcellular site of action of exfoliatin. J Invest Dermatol (1975) 1.04
Sulfone treatment of granuloma annulare. J Am Acad Dermatol (1985) 1.03
[On the autoradiographic labelling of Langerhans cells with H3-thymidine]. Arch Klin Exp Dermatol (1967) 1.03
Intra-epidermal eccrine poroma: a histochemical and enzyme-histochemical study. Cancer (1969) 1.02
Improvement of the diagnostic accuracy in pigmented skin lesions by epiluminescent light microscopy. Anticancer Res (1987) 1.02
A novel Ras antagonist regulates both oncogenic Ras and the tumor suppressor p53 in colon cancer cells. Mol Med (2000) 1.01